Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALTNASDAQ:GNLXNASDAQ:SNTIOTCMKTS:TRXDW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$1.32$1.47$0.73▼$3.78$83.40M0.79316,888 shs59,263 shsGNLXGenelux$2.90+0.7%$3.27$1.60▼$5.89$100.35M-0.36209,489 shs40,189 shsSNTISenti Biosciences$3.64-27.2%$3.53$1.52▼$16.94$94.66M2.32800,321 shs3.62 million shsTRXDWTransEnterix$0.15$0.15$0.12▼$0.18$21.42M2.568,250 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics0.00%-4.35%-13.16%+8.20%-61.74%GNLXGenelux0.00%+9.51%-6.49%-26.53%-15.29%SNTISenti Biosciences0.00%+28.87%+45.77%+10.62%+72.41%TRXDWTransEnterix0.00%0.00%0.00%0.00%+13,536.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGALTGalectin Therapeutics1.0932 of 5 stars3.00.00.00.02.21.70.0GNLXGenelux1.9323 of 5 stars3.62.00.00.03.80.00.0SNTISenti Biosciences2.8876 of 5 stars3.53.00.00.02.51.71.3TRXDWTransEnterixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 2.00Hold$11.00733.33% UpsideGNLXGenelux 3.20Buy$18.25529.31% UpsideSNTISenti Biosciences 3.00Buy$10.00174.73% UpsideTRXDWTransEnterix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRXDW, GALT, GNLX, and SNTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.01) per shareN/AGNLXGenelux$8K12,543.95N/AN/A$0.73 per share3.97SNTISenti Biosciences$2.56M36.97N/AN/A$15.02 per share0.24TRXDWTransEnterix$8.53M2.51$0.11 per share1.40$2.68 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$41.07M-$0.76N/AN/AN/AN/AN/A-163.15%5/21/2025 (Estimated)GNLXGenelux-$28.30M-$0.96N/AN/AN/AN/A-105.05%-80.16%5/8/2025 (Estimated)SNTISenti Biosciences-$71.06M-$12.03N/AN/AN/AN/A-154.84%-77.42%5/8/2025 (Estimated)TRXDWTransEnterix-$154.20M-$4.22N/AN/AN/A-2,149.15%-83.74%-64.94%N/ALatest TRXDW, GALT, GNLX, and SNTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025GALTGalectin Therapeutics-$0.20N/AN/AN/AN/AN/A5/8/2025N/AGNLXGenelux-$0.24N/AN/AN/AN/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/A3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ATRXDWTransEnterixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A1.131.13GNLXGeneluxN/A6.476.47SNTISenti BiosciencesN/A1.921.92TRXDWTransEnterix0.043.242.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%GNLXGenelux37.33%SNTISenti Biosciences25.73%TRXDWTransEnterix8.22%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics50.10%GNLXGenelux9.30%SNTISenti Biosciences10.70%TRXDWTransEnterix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics963.18 million31.32 millionOptionableGNLXGenelux1034.60 million31.33 millionNot OptionableSNTISenti Biosciences426.00 million4.30 millionNot OptionableTRXDWTransEnterixN/A142.78 millionN/ANot OptionableTRXDW, GALT, GNLX, and SNTI HeadlinesRecent News About These CompaniesLife Science Partners L P Synergy's Net WorthFebruary 9, 2024 | benzinga.comAsensus Surgical Inc (ASXC)January 30, 2024 | investing.comTransEnterix, Inc. (TRXDW)January 21, 2024 | ca.finance.yahoo.comSurgical Robots Global Market Report 2023June 13, 2023 | finance.yahoo.comAsensus Surgical (NYSEMKT: ASXC)May 27, 2023 | fool.comProfitable Strategic Report for the Robotic Endoscopy Devices Market with Business Strategies, Current Insight - openPRMay 12, 2023 | news.google.comAsia Pacific Minimally Invasive Gastrointestinal (GI) Surgical ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comGlobal Minimally Invasive Gastrointestinal (GI) Surgical Systems ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comAsensus Surgical, Inc. Reports Operating and Financial Results for ... - BenzingaMay 12, 2023 | news.google.comSurgical Robots Market 2023 is Booming Across the Globe by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comBariatric Surgery Devices Market Size, Trends, Share, Growth and ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comSurgical Robots Market: The global market is expected to grow at a ... - Digital JournalMay 10, 2023 | news.google.comMinimally Invasive Gastrointestinal (GI) Surgical Systems Market ... - Digital JournalMay 10, 2023 | news.google.comSurgical Robots Market to Grow at Rapid Pace with Advancements ... - Digital JournalMay 10, 2023 | news.google.comMedical Intelligent Auxiliary Robot Market 2023 Competitive Insights ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comGlobal Healthcare Robotics-Surgical Robots Market 2023, CAGR ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comSurgical Robots Market Excellent CAGR of 18%, Growth, Industry ... - Digital JournalMay 8, 2023 | news.google.comExponential Growth Expected for Intelligent Tissue Autonomous Robots Market With Complete SWOT Analysis by For - openPRMay 8, 2023 | news.google.comObesity Surgery Device Market Research Report 2023-2031 Market ... - The Northwestern ExaminerMay 7, 2023 | news.google.comGlobal Surgical Robotics Market Insights Report 2022, Trends ... - FylladeyMay 5, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRXDW, GALT, GNLX, and SNTI Company DescriptionsGalectin Therapeutics NASDAQ:GALT$1.32 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.32 +0.00 (+0.38%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Genelux NASDAQ:GNLX$2.90 +0.02 (+0.69%) Closing price 04:00 PM EasternExtended Trading$2.92 +0.02 (+0.83%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Senti Biosciences NASDAQ:SNTI$3.64 -1.36 (-27.20%) Closing price 04:00 PM EasternExtended Trading$3.25 -0.39 (-10.69%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.TransEnterix OTCMKTS:TRXDW$0.15 0.00 (0.00%) As of 03/7/2025TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
